Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

MannKind Corp (MNKD)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow MannKind's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
4.180 +0.100    +2.45%
16:00:01 - Closed. Currency in USD ( Disclaimer )
After Hours
4.250
+0.070
+1.675%
19:19:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,750,736
  • Bid/Ask: 4.180 / 4.310
  • Day's Range: 4.020 - 4.200
MannKind 4.180 +0.100 +2.45%

MannKind Corp Company Profile

 
Get an in-depth profile of MannKind Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

393

Equity Type

ORD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Contact Information

Address 1 Casper Street
Danbury, 06810
United States
Phone 818 661 5000
Fax -
Web www.mannkindcorp.com

Top Executives

Name Age Since Title
Derek LeRoith - - Member of Scientific Advisory Board
Jeremy Pettus - - Member of Scientific Advisory Board
Ronald J. Consiglio 77 2003 Independent Director
Michael A. Friedman 80 2003 Independent Director
Michael E. Castagna 44 2016 CEO & Director
Anne L. Peters - - Member of Scientific Advisory Board
John Anderson - - Member of Scientific Advisory Board
John B. Buse - - Chair of Scientific Advisory Board
Kent Kresa 86 2004 Independent Director
Satish K. Garg - - Member of Scientific Advisory Board
Kathleen Dungan - - Member of Scientific Advisory Board
Eda Cengiz - - Member of Scientific Advisory Board
Sabrina A. Kay 56 2020 Independent Director
James S. Shannon 66 2015 Independent Chairman
Kashif Latif - 2021 Member of Scientific Advisory Board
Philip Levin - 2021 Member of Scientific Advisory Board
Davida F. Kruger - 2021 Member of Scientific Advisory Board
David Maahs - 2021 Member of Scientific Advisory Board
Janet B. McGill - 2021 Member of Scientific Advisory Board
Bruce W. Bode - 2021 Member of Scientific Advisory Board
Anders L. Carlson - 2021 Member of Scientific Advisory Board
Thomas C. Blevins - 2021 Member of Scientific Advisory Board
Scott W. Lee - 2021 Member of Scientific Advisory Board
Anthony C. Hooper 69 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MNKD Comments

Write your thoughts about MannKind Corp
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
SonGoku Jabadaba
SonGokussj4 Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
-19 % pre? Why though?
Reply
1 0
Report
Smoil smoil
Smoil Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
If you dont know, you shouldnt invest at all.
Reply
0 1
Report
Steve Wayne
Hadrian Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
FDA decline of their drug application. It was due to a mfg issue at a 3rd party, though, so seems like an overreaction.
Reply
1 0
Report
SonGoku Jabadaba
SonGokussj4 Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I bought them because I believe! In Man(n)kind! :-D People are the future. Human civilization for the win!
Reply
1 0
Report
JG Capital
JGCapital Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
SonGoku Jabadaba Solid DD. Lol
Reply
0 0
Report
SonGoku Jabadaba
SonGokussj4 Oct 18, 2021 7:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I know. 310 % gain through the last few years. Not selling anytime soon :-D When Covid go, Mankind go up :-D
Reply
0 0
Report
Alexander Costa
Alexander Costa Jun 28, 2021 1:52AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
CCXI...FDA approval July 7th! Stock is about to skyrocket. Cancer treatment Drug 🤑 Gamechanger!! Yw
Reply
1 0
Report
Vova Vova
Vova Vova May 11, 2021 10:43AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The best price to buy
Reply
0 0
Report
Peter white
Peter white Apr 22, 2021 11:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-reach-milestone-development
Reply
0 0
Report
Peter white
Peter white Apr 22, 2021 11:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GO MNKD GO
Reply
0 0
Report
Peter white
Peter white Apr 22, 2021 11:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://mannkindcorp.com/wp-content/uploads/2021/04/Newsletter-April-2021-Final.pdf
Reply
0 0
Report
Crim Jamer
Crim Jamer Apr 21, 2021 12:46PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sold at the bottom after losing patience
Reply
0 1
Report
Peter white
Peter white Apr 19, 2021 9:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-reach-milestone-development
Reply
1 0
Report
Crim Jamer
Crim Jamer Apr 06, 2021 11:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MA50 broken, a close above 4.333 would be fine.
Reply
0 0
Report
Tedy Boulos
Tedy Boulos Apr 01, 2021 2:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Up up up
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email